PFE Research Update — August 28, 2026
Updated Thesis
Pfizer is a global biopharma company spanning oncology, cardiometabolic disease, vaccines and specialty medicines, with a meaningful but narrowing moat based on intellectual property, global regulatory and commercial infrastructure, manufacturing scale and established brands. Business quality is medium rather than high because TTM gross margin is strong at 71.3% and operating margin is 25.1%, but TTM net margin is only 6.8%, ROE is 4.9%, leverage remains elevated and earnings pressure is severe: earnings declined 108.5% year over year in the most recent quarter, reflecting major intangible impairments. The shares appear fairly valued rather than deeply mispriced at $28.01, trading at 2.51x sales, 36.82x trailing earnings, 14.53x free cash flow and 17.57x EV/EBITDA; the $31.49 fair-value estimate indicates 12.4% upside, while the $31 average analyst target implies 10.7% upside.
The investment grade as of this refresh is B — solid business quality. Medium-tier business, fair-tier valuation with 12.4% upside to $31.49 fair value.
Key Metrics at a Glance
- Revenue growth: +2.6% year over year
- Net margin: 6.8%
- Fair value upside: +12.4% to our estimate of $31
Current price: $28.01
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Pfizer Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full PFE research →](/stocks/PFE)